Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

Posted: April 21, 2025 at 2:44 am

WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cell therapy production capabilities.

Read more from the original source:
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

Related Posts